CAR-T cell therapy has transformed cancer treatment, giving new life to patients with few remaining options. By reprogramming a patient’s own T cells to identify and destroy cancer, it has redefined what’s possible in immunotherapy. But as science advances, so do its challenges, and its solutions. The next breakthrough is already here: bispecific CAR-T therapies that target both CD19 and CD20 antigens, offering a stronger, more lasting defence against relapse in B-cell malignancies.
Behind this cutting-edge therapy, however, lies an unsung hero, protein purification. Often overlooked, this process quietly determines how powerful, safe, and precise a CAR therapy will ultimately be. Every CAR molecule is built from a series of carefully engineered protein domains: the antigen-binding scFv, the transmembrane linkers, and the signalling molecules that activate immune responses. Each must be flawlessly folded, stable, and pure. Even a slight impurity can alter the way a CAR behaves, sometimes with serious consequences.
"Protein purification quietly determines how powerful, safe, and precise a CAR therapy will ultimately be."
Purification ensures that these proteins maintain their structure, function, and specificity. It is the unseen step that transforms a genetic blueprint into a reliable therapy. For bispecific CARs, where two scFvs work together to recognize CD19 and CD20, purity becomes even more critical. The slightest imbalance between the two binding arms can affect antigen recognition or lead to unwanted immune activation. Through meticulous purification, both domains retain the integrity needed to function in perfect harmony, ensuring every malignant cell is precisely targeted and eliminated.
In a field where safety and precision are inseparable, protein purification is what makes innovation trustworthy. High-purity proteins reduce off-target effects, enhance vector performance, and ensure predictable T-cell responses. They also minimize immunogenic risks, creating therapies that are not only effective but patient-safe. Without purification, even the most advanced CAR designs risk instability, inconsistency, or loss of function.
At Cellogen Therapeutics, I learned that the journey to therapeutic precision begins long before a T cell is engineered. It starts at the molecular level- with the clarity, stability, and functionality of purified proteins. Here, employ advanced purification techniques to isolate high-quality protein components that preserve their natural structure and bioactivity. Each CAR construct we develop undergoes this rigorous quality control, ensuring that it performs as intended when translated into clinical-grade therapy.
This dedication to purity is more than a technical requirement, it’s a philosophy. I am learning how it allows us to push boundaries in CD19/CD20 bispecific CAR-T therapy, ensuring consistent potency, reduced toxicity, and reliable outcomes for patients.
- Protein purification
.jpg)
